Your Partner in Transformation
CHICAGO, September 10, 2024–(BUSINESS WIRE)–HDI Global Insurance Company, the US subsidiary of international commercial insurer, HDI Global SE (HDI), today announced the launch of its excess Life Sciences Liability policy.
With up to $10M in available capacity, this enhanced solution provides customers with tailored cover for industry specific risks. Target classes include but are not limited to: – biotechnology and specialty pharmaceutical manufacturers and distributors, – non-invasive, invasive and permanently implantable medical device manufacturers, – blood plasma manufacturers, and – contract manufacturing and contract development manufacturing organizations (CMO & CDMO).
“HDI is committed to providing our insureds with bespoke solutions within the life sciences segment,” said Marco Hensel, Chief Underwriting Officer, HDI Global Insurance Company. “The launch of our US Life Sciences division is another example of HDI’s continued focus on growth within the region and to act as a true Partner in Transformation for our clients in times of exceptional acceleration within the medical realm.”
Brian Carlsen, who recently joined HDI as an Assistant Vice President (AVP) will serve as its new US Life Science Lead. He will be responsible for building out the company’s book of business within the region. Brian brings 16 years of underwriting experience, with the last 10 being focused exclusively on Life Science placements. Prior to joining HDI, he was the Underwriting Manager and Referral Underwriter for the East region at a Fortune 500 carrier. Brian is a graduate of Fairfield University with a major in communications.
“HDI is excited to have Brian join our US casualty team,” said Dani Maurer, Head of HDI’s Liability Global Risk Division. “He brings extensive experience with small to large LS firms, underwriting accounts ranging from start-ups to large multinational corporations. His expertise will play a key role in HDI’s product line expansion within the US.”
More information about HDI’s life sciences enhanced product offering can be obtained at Life Science (hdi.global).
To find out more about the services of HDI Global Insurance Company U.S., click here: https://www.hdi.global/en-us/about-us/locations-contacts/america/united-states/contacts/.
About HDI Global SE (HDI)
As a commercial and specialty lines insurer, HDI meets the needs of SMEs, industrial companies, middle market, and corporate customers with insurance solutions that are specifically tailored to their requirements. In addition to HDI’s prominent position in the German and broader European market, the company has access to its own worldwide HDI Global Network covering more than 175 countries through its own HDI foreign branch offices, subsidiaries, affiliated companies, and network partners.
Story continues
In the United States, HDI operates through its three (3) wholly owned subsidiaries, HDI Global Insurance Company, a commercial property and casualty insurer headquartered in Chicago, IL and licensed in all 50 states, Washington D.C., Puerto Rico, and the U.S. Virgin Islands, HDI Global Select Insurance Company, a commercial property and casualty insurer licensed in Washington D.C., and in all US states with the exception of Rhode Island, and HDI Specialty Insurance Company, an Illinois domestic surplus lines insurer who provides both primary and excess coverage to specialized industries and is also authorized to write business nationwide.
Acting as a Partner in Transformation, HDI leads more than 5,000 International Programmes and offers its multinational customers compliant coverage worldwide. HDI is the Industrial Lines Division of the Talanx Group and has been a leading insurer for several decades. Approximately 5,000 employees in this division generated insurance revenue (gross) of approx. EUR 9.1 billion in the year 2023 (according to IFRS 17).
The rating agency Standard & Poor’s has given the Talanx Primary Group a financial strength rating of A+/stable (strong). Talanx AG is listed on the Frankfurt Stock Ex-change in the MDAX.
Disclaimer
This news release may include forward-looking statements which are based on certain assumptions, expectations and opinions of the management of Talanx AG and HDI Global SE. These statements are, therefore, subject to certain known or unknown risks and uncertainties. A variety of factors, many of which are beyond Talanx AG’s and HDI Global SE’s control, affect our business activities, business strategy, results, performance and achievements. Should one or more of these factors or risks or uncertainties materialize, actual results, performance or achievements of Talanx AG and HDI Global SE may vary materially from those expressed or implied in the relevant forward-looking statement. Talanx AG and HDI Global SE do not guarantee that the assumptions underlying such forward-looking statements are free from errors nor do Talanx AG and HDI Global SE accept any responsibility for the actual occurrence of the forecasted developments. Talanx AG and HDI Global SE neither intend, nor assume any obligation, to update or revise these forward-looking statements in light of developments which differ from those anticipated.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240910756211/en/
Contacts
For media enquiries please contact:
George Contoravdis
Tel: +1 312 589 6752
E-Mail: george.contoravdis@us.hdi.global
Dr Frederic Strohm
Tel.: +49 511 3747 2117
E-Mail: frederic.strohm@hdi.global
Christoph Boßmeyer-Hortsch
Tel.: +49 511 6455 9515
E-Mail: christoph.bossmeyer-hortsch@hdi.global
Source link : http://www.bing.com/news/apiclick.aspx?ref=FexRss&aid=&tid=66e04d9d2ed8407c844c1a0904a9a49f&url=https%3A%2F%2Ffinance.yahoo.com%2Fnews%2Fhdi-global-us-unveils-excess-130200787.html&c=7609421707409952101&mkt=en-us
Author :
Publish date : 2024-09-10 02:02:00
Copyright for syndicated content belongs to the linked Source.